1. An In Situ Depot for Continuous Evolution of Gaseous H 2 Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis.
- Author
-
Wan WL, Lin YJ, Shih PC, Bow YR, Cui Q, Chang Y, Chia WT, and Sung HW
- Subjects
- Animals, Humans, Magnesium chemistry, Mice, Organometallic Compounds chemical synthesis, Organometallic Compounds chemistry, Osteoarthritis metabolism, Osteoarthritis pathology, Particle Size, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, RAW 264.7 Cells, Surface Properties, Hydrogen chemistry, Magnesium therapeutic use, Organometallic Compounds therapeutic use, Osteoarthritis drug therapy, Polylactic Acid-Polyglycolic Acid Copolymer therapeutic use
- Abstract
Inflammation is involved in many human pathologies, including osteoarthritis (OA). Hydrogen (H
2 ) is known to have anti-inflammatory effects; however, the bioavailability of directly administered H2 gas is typically poor. Herein, a local delivery system that can provide a high therapeutic concentration of gaseous H2 at inflamed tissues is proposed. The delivery system comprises poly(lactic-co-glycolic acid) microparticles that contain magnesium powder (Mg@PLGA MPs). Mg@PLGA MPs that are intra-muscularly injected close to the OA knee in a mouse model can act as an in situ depot that can evolve gaseous H2 continuously, mediated by the cycle of passivation/activation of Mg in body fluids, at a concentration that exceeds its therapeutic threshold. The analytical data that are obtained in the biochemical and histological studies indicate that the proposed Mg@PLGA MPs can effectively mitigate tissue inflammation and prevent cartilage from destruction, arresting the progression of OA changes., (© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2018
- Full Text
- View/download PDF